Paul Thomen

Thursday, 9 May 2013

Tysabri, Avonex, Copaxone Multiple Sclerosis Market Analysis 2022 adds “Copaxone (Multiple Sclerosis) – Forecast and Market Analysis to 2022” “Avonex (Multiple Sclerosis) – Forecast and Market Analysis to 2022” & “Tysabri (Multiple Sclerosis) – Forecast and Market Analysis to 2022”new report on its database.

PharmaPoint Drug Evaluation report, “Tysabri, Avonex, Copaxone (Multiple Sclerosis) – Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance of first-line injectable DMTs, including the interferon beta (IFNß) agents: Bayer’s Betaseron/Betaferon (IFNß-1b), Biogen’s Avonex (IFNß-1a) and Merck’s Rebif (IFNß-1a), and Teva’s Copaxone (glatiramer acetate), has been a salient feature of the MS therapeutics market. However, the competitive landscape is undergoing significant change with the emergence of oral therapies, several pipeline products with notable efficacies, and looming generics/biosimilars following the patent expiries of key branded products during the forecast period. In addition, the entry of new companies such as Sanofi/Genzyme and F. Hoffmann-La-Roche/Genentech will challenge the position of the established players in the MS marketplace.

Copaxone Market Analysis to 2022

Teva’s Copaxone (glatiramer acetate; formerly known as copolymer-1) is a synthesized polypeptide mixture containing a random combination of L-lysine, L-glutamic acid, L-alanine and L-tyrosine, the most common amino acids present in myelin basic protein (MBP); a key structural component of the myelin sheath. Having gained FDA approval in 1996 for the first-line treatment of RRMS to reduce the frequency of relapses, Copaxone became the first non- IFNß-based DMT available for MS. Copaxone surpassed Avonex in 2008 as the top-selling MS drug, driven primarily by good tolerability and efficacy that is comparable to the interferon betas. In 2009, the FDA expanded the Copaxone label to include the treatment of patients with CIS, thereby further enhancing the drug’s market share.

Avonex Market Analysis to 2022

Biogen Idec’s Avonex (interferon beta-1a) is an IM-administered immunomodulatory agent indicated for the first-line treatment of RRMS and for individuals presenting with CIS. Avonex was approved by the FDA in 1996 and received Orphan Drug status, giving it market exclusivity for seven years in the US until 2003. Despite the Orphan Drug status of Betaseron that was still in effect at the time, Avonex was granted marketing approval because it was proven to be a different formulation of IFNß to Betaseron.

Tysabri Market Analysis to 2022

Tysabri gained FDA approval in 2004 as a monotherapy for the treatment of RRMS to delay the accumulation of physical disability and reduce the frequency of clinical exacerbations. However, Tysabri was temporarily withdrawn from the market by the manufacturer in 2005 after several reported cases of fatal John Cunningham virus (JCV)-induced progressive multifocal leukoencephalopathy (PML) in Tysabri-treated patients. Following a safety review, Tysabri was reintroduced into the global markets in 2006 under the special TOUCH restricted distribution program.


- Overview of Multiple Sclerosis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Tysabri including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Tysabri for the top ten countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Canada, China and India

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Multiple Sclerosis
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Tysabri performance
- Obtain sales forecast for Tysabri from 2012-2022 in top ten countries (the US, France, Germany, Italy, Spain, the UK, Japan, Canada, China and India)

Table of Content

1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 12
3.1.3 Classification of Multiple Sclerosis 13
3.2 Symptoms 15
3.2.1 Prognosis 16
3.2.2 Quality of Life 17
4 Disease Management 18
4.1 Diagnosis 18
4.2 Treatment Overview 21
4.2.1 Management of Acute Relapse 22
4.2.2 Treatment with Disease-Modifying Therapies 22
4.2.3 Symptomatic Therapies 25
5 Competitive Assessment 26
5.1 Overview 26
5.2 Strategic Competitor Assessment 27
6 Copaxone (glatiramer acetate; copolymer-1) 29
6.1 Overview 29
6.2 Efficacy 30
6.3 Safety 31
6.4 SWOT Analysis 31
6.5 Forecast 34
7 Appendix 35
7.1 Bibliography 35
7.2 Abbreviations 40
7.3 Methodology 42
7.4 Forecasting Methodology 42
7.4.1 Diagnosed MS patients 42
7.4.2 Percent Drug-Treated Patients 43
7.4.3 General Pricing Assumptions 43
7.4.4 Individual Drug Assumptions 44
7.4.5 Generic Erosion 44
7.5 Physicians and Specialists Included in This Report 45
7.6 Primary Research – Prescriber Survey 46
7.7 About the Authors 47
7.7.1 Analysts 47
7.7.2 Global Head of Healthcare 48
7.8 About GlobalData 49
7.9 Contact Us 49
7.10 Disclaimer 49

For more details contact Mr. Priyank Tiwari: / +18883915441

No comments:

Post a Comment

Note: only a member of this blog may post a comment.